Cancer Associated Aberrant Protein O-Glycosylation Can Modify Antigen Processing and Immune Response

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Madsen, Caroline B ^a   Petersen, Cecilie ^a   Lavrsen, Kirstine ^a   Harndahl, Mikkel ^a   Buus, Søren ^a   Clausen, Henrik ^a   Pedersen, Anders E ^a   Wandall, Hans H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GLYCOPEPTIDE; GLYCOPROTEIN P 15095; HLA A2 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUCIN 1; MUCIN 2; OVALBUMIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOREACTIVITY; INTERFERON GAMMA RELEASE ASSAY; MOUSE; NEOPLASM; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; SEQUENCE HOMOLOGY; T LYMPHOCYTE; TANDEM REPEAT;

ACETYLGALACTOSAMINE; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; GLYCOSYLATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MICE; MOLECULAR SEQUENCE DATA; MUCIN-1; NEOPLASMS; PEPTIDES; PROTEIN BINDING;

MUS; MUS MUSCULUS;

EID: 84870044166     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050139     Document Type: Article

References (76)

1. Dougan M, Dranoff G, (2009) Immune therapy for cancer. Annu Rev Immunol 27: 83-117.
2. Cho HI, Celis E, (2009) Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 69: 9012-9019.
3. Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, et al. (2009) TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol 183: 3634-3641.
4. Sikora AG, Jaffarzad N, Hailemichael Y, Gelbard A, Stonier SW, et al. (2009) IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol 182: 7398-7407.
5. Sinnathamby G, Lauer P, Zerfass J, Hanson B, Karabudak A, et al. (2009) Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. J Immunother 32: 856-869.
6. Gelderman KA, Tomlinson S, Ross GD, Gorter A (2004) Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25: 158-164. 10.1016/j.it.2004.01.008 [doi];S1471490604000262 [pii].
7. Wang SY, Weiner G (2008) Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther 8: 759-768. 10.1517/14712598.8.6.759 [doi];10.1517/14712598.8.6.759 [pii].
8. Kiessling A, Fussel S, Wehner R, Bachmann M, Wirth MP, et al. (2008) Advances in specific immunotherapy for prostate cancer. Eur Urol 53: 694-708.
9. Springer GF, (1984) T and Tn, general carcinoma autoantigens. Science 224: 1198-1206.
10. Hakomori S (2002) Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A 99: 10231-10233. 10.1073/pnas.172380699 [doi];172380699 [pii].
11. Sorensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, et al. (2006) Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 16: 96-107.
12. Tarp MA, Sorensen AL, Mandel U, Paulsen H, Burchell J, et al. (2007) Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 17: 197-209.
13. Pedersen JW, Blixt O, Bennett EP, Tarp MA, Dar I, et al. (2010) Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer. 10.1002/ijc.25778 [doi].
14. Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, et al. (2010) Cancer biomarkers defined by autoantibody signatures to aberrant o-glycopeptide epitopes. Cancer Res 70: 1306-1313.
15. Xu Y, Gendler SJ, Franco A (2004) Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J Exp Med 199: 707-716. 10.1084/jem.20031865 [doi];jem.20031865 [pii].
16. Tarp MA, Clausen H (2008) Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 1780: 546-563. S0304-4165(07)00216-4 [pii];10.1016/j.bbagen.2007.09.010 [doi].
17. Unger WW, van KY (2011) 'Dressed for success' C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells. Curr Opin Immunol 23: 131-137. S0952-7915(10)00199-8 [pii];10.1016/j.coi.2010.11.011 [doi].
18. Kurts C, Robinson BW, Knolle PA (2010) Cross-priming in health and disease. Nat Rev Immunol 10: 403-414. nri2780 [pii];10.1038/nri2780 [doi].
19. Napoletano C, Rughetti A, gervig Tarp MP, Coleman J, Bennett EP, et al. (2007) Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res 67: 8358-8367.
20. Denda-Nagai K, Aida S, Saba K, Suzuki K, Moriyama S, et al. (2010) Distribution and function of macrophage galactose-type C-type lectin 2 (MGL2/CD301b): efficient uptake and presentation of glycosylated antigens by dendritic cells. J Biol Chem 285: 19193-19204. M110.113613 [pii];10.1074/jbc.M110.113613 [doi].
21. Blixt O, Bueti D, Burford B, Allen D, Julien S, et al. (2011) Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res 13: R25. bcr2841 [pii];10.1186/bcr2841 [doi].
22. Lavrsen K, Madsen CB, Rasch MG, Woetmann A, Odum N, et al. (2012) Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj J. 10.1007/s10719-012-9437-7 [doi].
23. Danielczyk A, Stahn R, Faulstich D, Loffler A, Marten A, et al. (2006) PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother 55: 1337-1347. 10.1007/s00262-006-0135-9 [doi].
24. Ninkovic T, Kinarsky L, Engelmann K, Pisarev V, Sherman S, et al. (2009) Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Mol Immunol 47: 131-140.
25. Apostolopoulos V, Yuriev E, Ramsland PA, Halton J, Osinski C, et al. (2003) A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci U S A 100: 15029-15034. 10.1073/pnas.2432220100 [doi];2432220100 [pii].
26. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M (1999) MUC1 and cancer. Biochim Biophys Acta 1455: 301-313. S0925-4439(99)00055-1 [pii].
27. Gendler SJ, Spicer AP, Lalani EN, Duhig T, Peat N, et al. (1991) Structure and biology of a carcinoma-associated mucin, MUC1. Am Rev Respir Dis 144: S42-S47.
28. Heukamp LC, van der Burg SH, Drijfhout JW, Melief CJ, Taylor-Papadimitriou J, et al. (2001) Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice. Int J Cancer 91: 385-392.
29. Barratt-Boyes SM, Vlad A, Finn OJ, (1999) Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clin Cancer Res 5: 1918-1924.
30. Apostolopoulos V, Haurum JS, McKenzie IF, (1997) MUC1 peptide epitopes associated with five different H-2 class I molecules. Eur J Immunol 27: 2579-2587.
31. Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF, (2000) Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine 18: 2059-2071.
32. Tsang KY, Palena C, Gulley J, Arlen P, Schlom J, (2004) A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res 10: 2139-2149.
33. Heukamp LC, van HT, Ossendorp F, Burchell JM, Melief CJ, et al. (2002) Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. J Immunother 25: 46-56.
34. Pinkhasov J, Alvarez ML, Pathangey LB, Tinder TL, Mason HS, et al. (2010) Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse model. Cancer Immunol Immunother 59: 1801-1811. 10.1007/s00262-010-0906-1 [doi].
35. Soares MM, Mehta V, Finn OJ, (2001) Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 166: 6555-6563.
36. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, Livingston PO, et al. (2001) Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer 93: 97-106. 10.1002/ijc.1286 [pii].
37. Adluri S, Gilewski T, Zhang S, Ramnath V, Ragupathi G, et al. (1999) Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21. Br J Cancer 79: 1806-1812.
38. Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, et al. (2000) Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 6: 1693-1701.
39. Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, et al. (2008) Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 14: 3060-3069. 14/10/3060 [pii];10.1158/1078-0432.CCR-08-0126 [doi].
40. Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, et al. (2011) A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 17: 7164-7173. 1078-0432.CCR-11-0649 [pii];10.1158/1078-0432.CCR-11-0649 [doi].
41. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, et al. (2008) A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol 3: 735-744. 10.1097/JTO.0b013e31817c6b4f [doi];01243894-200807000-00008 [pii].
42. Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, et al. (2011) Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 19: 990-999. mt2010289 [pii];10.1038/mt.2010.289 [doi].
43. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, et al. (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96: 3102-3108.
44. Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, et al. (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66: 5910-5918. 66/11/5910 [pii];10.1158/0008-5472.CAN-05-3905 [doi].
45. Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, et al. (2006) Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 8: R27.
46. Loveland BE, Zhao A, White S, Gan H, Hamilton K, et al. (2006) Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 12: 869-877. 12/3/869 [pii];10.1158/1078-0432.CCR-05-1574 [doi].
47. Rong Y, Qin X, Jin D, Lou W, Wu L, et al. (2011) A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin Exp Med. 10.1007/s10238-011-0159-0 [doi].
48. Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, et al. (2009) MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs 27: 379-386. 10.1007/s10637-008-9187-3 [doi].
49. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, et al. (2011) Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 12: 1125-1133. S1470-2045(11)70259-5 [pii];10.1016/S1470-2045(11)70259-5 [doi].
50. Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, et al. (2011) A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 60: 261-271. 10.1007/s00262-010-0935-9 [doi].
51. Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, et al. (2003) Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 5: 690-699. 10.1002/jgm.397 [doi].
52. Madan RA, Arlen PM, Gulley JL (2007) PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther 7: 543-554. 10.1517/14712598.7.4.543 [doi].
53. Ohyanagi F, Horai T, Sekine I, Yamamoto N, Nakagawa K, et al. (2011) Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study. Jpn J Clin Oncol 41: 718-722. hyr021 [pii];10.1093/jjco/hyr021 [doi].
54. Palmer M, Parker J, Modi S, Butts C, Smylie M, et al. (2001) Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 3: 49-57.
55. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, et al. (2005) Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23: 6674-6681. 23/27/6674 [pii];10.1200/JCO.2005.13.011 [doi].
56. Butts C, Murray RN, Smith CJ, Ellis PM, Jasas K, et al. (2010) A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer 11: 391-395. S1525-7304(11)70044-4 [pii];10.3816/CLC.2010.n.101 [doi].
57. Butts C, Maksymiuk A, Goss G, Soulieres D, Marshall E, et al. (2011) Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 137: 1337-1342. 10.1007/s00432-011-1003-3 [doi].
58. Ryan SO, Vlad AM, Islam K, Gariepy J, Finn OJ, (2009) Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. Biol Chem 390: 611-618.
59. Singh SK, Streng-Ouwehand I, Litjens M, Kalay H, Saeland E, et al. (2010) Tumour-associated glycan modifications of antigen enhance MGL2 dependent uptake and MHC class I restricted CD8 T cell responses. Int J Cancer. 10.1002/ijc.25458 [doi].
60. Ninkovic T, Hanisch FG, (2007) O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes. J Immunol 179: 2380-2388.
61. Hanisch FG, Schwientek T, Von Bergwelt-Baildon MS, Schultze JL, Finn O, (2003) O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur J Immunol 33: 3242-3254.
62. Wandall HH, Hassan H, Mirgorodskaya E, Kristensen AK, Roepstorff P, et al. (1997) Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1,-T2, and-T3. J Biol Chem 272: 23503-23514.
63. Bennett EP, Hassan H, Mandel U, Mirgorodskaya E, Roepstorff P, et al. (1998) Cloning of a human UDP-N-acetyl-alpha-D-Galactosamine:polypeptide N-acetylgalactosaminyltransferase that complements other GalNAc-transferases in complete O-glycosylation of the MUC1 tandem repeat. J Biol Chem 273: 30472-30481.
64. Greenberg PD, Kern DE, Cheever MA, (1985) Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med 161: 1122-1134.
65. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, et al. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358: 2698-2703. 358/25/2698 [pii];10.1056/NEJMoa0800251 [doi].
66. Rughetti A, Pellicciotta I, Biffoni M, Backstrom M, Link T, et al. (2005) Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol 174: 7764-7772. 174/12/7764 [pii].
67. Hiltbold EM, Alter MD, Ciborowski P, Finn OJ, (1999) Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells. Cell Immunol 194: 143-149.
68. Tenzer S, Stoltze L, Schonfisch B, Dengjel J, Muller M, et al. (2004) Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility. J Immunol 172: 1083-1091.
69. Sorokin AV, Kim ER, Ovchinnikov LP (2009) Proteasome system of protein degradation and processing. Biochemistry (Mosc) 74: 1411-1442. BCM74131411 [pii].
70. Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, et al. (2012) Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A 109: 261-266. 1115166109 [pii];10.1073/pnas.1115166109 [doi].
71. Harndahl M, Justesen S, Lamberth K, Roder G, Nielsen M, et al. (2009) Peptide binding to HLA class I molecules: homogenous, high-throughput screening, and affinity assays. J Biomol Screen 14: 173-180. 1087057108329453 [pii];10.1177/1087057108329453 [doi].
72. Harndahl M, Rasmussen M, Roder G, Buus S (2010) Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. J Immunol Methods. S0022-1759(10)00324-8 [pii];10.1016/j.jim.2010.10.012 [doi].
73. Hugo P, Kappler JW, McCormack JE, Marrack P, (1993) Fibroblasts can induce thymocyte positive selection in vivo. Proc Natl Acad Sci U S A 90: 10335-10339.
74. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN (1997) Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726. S1074-7613(00)80447-1 [pii].
75. Rock KL, Rothstein L, Gamble S, (1990) Generation of class I MHC-restricted T-T hybridomas. J Immunol 145: 804-811.
76. Met O, Buus S, Claesson MH, (2003) Peptide-loaded dendritic cells prime and activate MHC-class I-restricted T cells more efficiently than protein-loaded cross-presenting DC. Cell Immunol 222: 126-133.